Antioxidative Mesh Adhesive to Prevent Seroma - PROJECT SUMMARY Seromas and hematomas are common complications following abdominoplasty and other large soft tissue surgeries, occurring in up to 20~30% of cases. These fluid collections can lead to infection, delayed healing, repeat interventions, and an estimated $5,000~$10,000 in additional healthcare costs per patient. Current prevention strategies, such as surgical drains and tension sutures, are limited. Drains must often remain for weeks, causing discomfort and infection risk, while tension sutures can cause tissue injury and impaired perfusion. Commercial adhesives (cyanoacrylates, fibrin sealants, lysine-derived urethanes) have shown limited efficacy due to internal-use toxicity, inadequate bonding strength, or lack of bioactivity. Critically, none address oxidative stress, a key driver of inflammation, impaired angiogenesis, and fibrosis after surgery. There is no FDA- approved adhesive specifically designed to both eliminate surgical dead space and modulate the wound environment to improve healing. Tissuelock aims to develop a novel antioxidative fiber mesh adhesive that seals surgical planes while actively promoting a regenerative microenvironment. The mesh is composed of co-polymers functionalized with N- hydroxysuccinimide esters for rapid covalent tissue bonding, α-lipoic acid-derived thioether and disulfide bonds for sustained reactive oxygen species scavenging and anti-inflammatory activity, and amine-modified hyaluronic acid to promote angiogenesis and strengthen tissue integration. The porous mesh conforms to complex tissue geometries, provides mechanical stability, and facilitates host cell infiltration, while its antioxidative chemistry promotes macrophage polarization toward a pro-regenerative phenotype, enabling vascularized tissue remodeling and reduced fibrosis. In Phase I, Aim 1 will develop antioxidative fiber meshes with performance benchmarked to comparable products under simulated surgical conditions, including adhesion testing on multiple tissue types (human cadaver abdominal wall) compared to commercial controls, evaluation of antioxidative capacity, and cytocompatibility assessment. Aim 2 will evaluate the optimized meshes in a rat abdominoplasty model, quantifying seroma volume by ultrasound and assessing histological and immunohistochemical markers of inflammation, angiogenesis, oxidative stress, and fibrosis. The expected outcome of Phase I is an optimized antioxidative fiber mesh adhesive with defined performance benchmarks, validated preclinically, and ready for regulatory engagement. Given its novel internal use and bioactive chemistry, we anticipate a PMA regulatory pathway. Phase II will advance to large-animal validation, ISO 10993 biocompatibility testing, and FDA Q-Submission to finalize preclinical and clinical requirements for IDE submission. Successful translation will address a major unmet surgical need, potentially transforming surgical dead space management and improving outcomes across reconstructive, aesthetic, and general surgery.